2022 / 06

Next Paper
DOI: 10.24075/brsmu.2022.071

ORIGINAL RESEARCH

Efficacy of favipiravir and molnupiravir against novel SARS-CoV-2 variants in vitro and in vivo

Siniavin AE1,2, Russu LI1, Vasina DV1, Shidlovskaya EV1, Kuznetsova NA1, Gushchin VA1,3, Gintsburg AL1,4
About authors

1 Gamaleya National Research Center for Epidemiology and Microbiology, Moscow, Russia

2 Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia

3 Lomonosov Moscow State University, Moscow, Russia

4 Sechenov University, Moscow, Russia

Correspondence should be addressed: Andrey E. Sinyavin
Gamalei, 16, Moscow, 123098, Russia; ur.xednay@39isyerdna

About paper

Funding: the study was supported by the Russian Ministry of Health, grant № 121111200070-4 (P16).

Acknowledgments: the authors would like to thank the staff of N.I. N.F. Gamaleya A. Zakharova and T. Remizov for organizing the supply of reagents for the study.

Author contribution: Sinyavin AE — design of the experiment, study of antiviral activity, data analysis, writing the text; Russu LI — work with the virus and animals; Vasina DV — work with animals; Shidlovskaya EV, Kuznetsova NA — PCR analysis, data processing; Gushchin VA — research supervision, text editing; Gunzburg AL — approval of the research concept.

Compliance with ethical standards: the study was approved by the ethics committee of the Federal State Budgetary Institution “N.N. N.F. Gamaleya" of the Ministry of Health of the Russian Federation (protocol № 27 of June 6, 2022); conducted in compliance with the principles of the Declaration of Helsinki of the World Medical Association.

Received: 2022-12-05 Accepted: 2022-12-20 Published online: 2022-12-31
|
Fig. 1. Cytotoxicity study of Molnupiravir (A) and Favipiravir (B) using Vero E6 cells
Fig. 2. Antiviral activity of Molnupiravir (EIDD-2801) (A) and Favipiravir (B) against four different variants of the SARS-CoV-2 virus
Fig. 3. The effectiveness of drugs against the Wuhan and Omicron BA.5 in animal models. Animals weight changes are presented, as well as the values of viral load and virus titer in the lungs for each animal in the corresponding group. ANOVA with Tukey's post hoc test: * — p < 0.05; ** — p < 0.01